FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average I	hurden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or S	Section	30(h)	of the	Investr	nent C	ompany Act	of 1940						
1. Name and Address of Reporting Person* <u>Kelly Lisa</u>				VI	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle)														X	Office belov	er (give title v)	Other below)	(specify
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 05/24/2012									:	SVP, Huma	n Resources		
130 WAVERLY ST				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)													ine) X Form filed by One Reporting Person					
CAMBRIDGE MA 02139													Form filed by More than One Reporting Person					
(City)	(S	tate) ((Zip)															
		Tab	le I - N	lon-Deriv	ative	Sec	uritie	s Ac	quire	d, D	sposed o	f, or B	enefici	ially	Owne	ed		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/N				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				nd 5) Sec Ben Owi		urities eficially ned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price			action(s) 3 and 4)		(Instr. 4)
Common	Stock			05/24/2	012				S ⁽¹⁾		900	D	\$62.74	4 (2)(3)	2	2,355	D	
Common	Stock			05/24/2	012				S ⁽¹⁾		5,106	D	\$63.38	3(3)(4)	1	7,249	D	
Common	Stock															1,667	I	401(k)
		Ta	able II								osed of, convertib				vned			
Derivative Conversion Date Exec Security or Exercise (Month/Day/Year) if an		if any	emed 4. Transaction Code (Instr. 8)					6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			ative rity	tive derivative ity Securities	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Codo	,,	(0)	(D)	Date	1-1-	Expiration	Title	Amount or Number of					

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Ms.\ Kelly-Croswell's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- $2. Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$62.74 \ (range \ \$62.25 \ to \ \$62.99).$
- 3. Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$63.38 (range \$63.06 to \$63.62).

Remarks:

David T. Howton, Attorney-In-Fact

05/29/2011

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.